CRI (CD35) As a Cellular Receptor for CIq
CRI (CD35) 作为 CIq 的细胞受体
基本信息
- 批准号:7019994
- 负责人:
- 金额:$ 45.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-09-30 至 2008-02-29
- 项目状态:已结题
- 来源:
- 关键词:B lymphocyteCD antigensautoimmune disorderbinding proteinsbiological signal transductionchickensclinical researchcomplement deficiencycomplement receptorhuman subjectimmune complexmacrophagemannosemonoclonal antibodymonocyteneutrophilpatient oriented researchphagocytosisreceptor bindingrecombinant proteinstissue /cell culture
项目摘要
DESCRIPTION (provided by applicant): Clq and MBL participate in tissue remodeling by tagging apoptotic and necrotic tissue, respectively. Clq deficiency is associated with a 93% chance of developing a lupus-like syndrome characterized by an early onset of severe rash and nephritis with high morbidity and mortality. This striking association indicates an important role for Clq in the prevention of autoimmunity, which must depend upon interactions with Clq receptors, since the phenotypes of C4 and C2 deficiencies are much less severe. Our laboratories have demonstrated that Clq and MBL bind specifically to complement receptor 1 (CD35) on hematopoietic cells. Two hypotheses are proposed to link Clq deficiency and autoimmunity. First, Clq-dependent ligation of CD35 on B cells may evoke a negative signal that inhibits B cell proliferation. Second, Clq-dependent opsonization of apoptotic material and clearance by a CD35+ phagocyte prevents autoantigens from becoming immunogenic. The three aims of this proposal are: (1) To determine more precisely the binding site on CD35 for Clq and the binding site on Clq for CD35. (2) To define the functional consequences of Clq ligation of CD35 on leukocytes including the relevant signaling pathway utilized by CD35 on B cells and phagocytic cells. (3) To evaluate the ability of Clq-opsonized apoptotic material to be ingested via a CD35-mediated pathway and how cell surface calreticulin modulates this process. Although genetically determined Clq deficiency is a rare condition, it emphasizes the importance of Clq and its receptors. These studies of Clq receptor biology will provide insights into the pathogenesis of more common autoimmune diseases.
描述(申请人提供):Clq和MBL分别通过标记凋亡组织和坏死组织参与组织重塑。Clq缺乏症有93%的机会发展为狼疮样综合征,其特征是早期出现严重皮疹和肾炎,发病率和死亡率高。这种惊人的关联表明Clq在预防自身免疫中的重要作用,这必须依赖于与Clq受体的相互作用,因为C4和C2缺陷的表型要轻得多。我们的实验室已经证明Clq和MBL特异性结合造血细胞上的补体受体1 (CD35)。Clq缺乏和自身免疫之间存在两种联系。首先,CD35在B细胞上的clq依赖性连接可能引起抑制B细胞增殖的负信号。其次,clq依赖性的凋亡物质的调控和CD35+吞噬细胞的清除阻止了自身抗原的免疫原性。本提案的三个目的是:(1)更精确地确定Clq在CD35上的结合位点和CD35在Clq上的结合位点。(2)明确CD35 Clq连接对白细胞的功能影响,包括CD35对B细胞和吞噬细胞利用的相关信号通路。(3)评估clq活化的凋亡物质通过cd35介导的途径被摄取的能力,以及细胞表面钙调蛋白如何调节这一过程。虽然由基因决定的Clq缺乏症是一种罕见的疾病,但它强调了Clq及其受体的重要性。这些Clq受体生物学的研究将为更常见的自身免疫性疾病的发病机制提供见解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANNE NICHOLSON-WELLER其他文献
ANNE NICHOLSON-WELLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANNE NICHOLSON-WELLER', 18)}}的其他基金
CR1 (CD35) AS A CELLULAR RECEPTOR FOR CIQ
CR1 (CD35) 作为 CIQ 的细胞受体
- 批准号:
2887721 - 财政年份:1998
- 资助金额:
$ 45.01万 - 项目类别:
CRI (CD35) As a Cellular Receptor for CIq
CRI (CD35) 作为 CIq 的细胞受体
- 批准号:
6711776 - 财政年份:1998
- 资助金额:
$ 45.01万 - 项目类别:
CR1 (CD35) AS A CELLULAR RECEPTOR FOR CIQ
CR1 (CD35) 作为 CIQ 的细胞受体
- 批准号:
6170691 - 财政年份:1998
- 资助金额:
$ 45.01万 - 项目类别:
CR1 (CD35) AS A CELLULAR RECEPTOR FOR CIQ
CR1 (CD35) 作为 CIQ 的细胞受体
- 批准号:
6373824 - 财政年份:1998
- 资助金额:
$ 45.01万 - 项目类别:
CR1 (CD35) AS A CELLULAR RECEPTOR FOR CIQ
CR1 (CD35) 作为 CIQ 的细胞受体
- 批准号:
2607884 - 财政年份:1998
- 资助金额:
$ 45.01万 - 项目类别:
CRI (CD35) As a Cellular Receptor for CIq
CRI (CD35) 作为 CIq 的细胞受体
- 批准号:
6866409 - 财政年份:1998
- 资助金额:
$ 45.01万 - 项目类别:
CRI (CD35) As a Cellular Receptor for CIq
CRI (CD35) 作为 CIq 的细胞受体
- 批准号:
7191597 - 财政年份:1998
- 资助金额:
$ 45.01万 - 项目类别:
CRI (CD35) As a Cellular Receptor for CIq
CRI (CD35) 作为 CIq 的细胞受体
- 批准号:
6630106 - 财政年份:1998
- 资助金额:
$ 45.01万 - 项目类别:
COMPLEMENT--PLASMA MEMBRANE FUNCTIONAL INTERACTIONS
补体--质膜功能相互作用
- 批准号:
2028181 - 财政年份:1989
- 资助金额:
$ 45.01万 - 项目类别:
COMPLEMENT--PLASMA MEMBRANE FUNCTIONAL INTERACTIONS
补体--质膜功能相互作用
- 批准号:
6330018 - 财政年份:1989
- 资助金额:
$ 45.01万 - 项目类别:
相似海外基金
Analysis of expression of Cd antigens in retinoblastoma, and its application for disease classification and therapeutic strategy
视网膜母细胞瘤中Cd抗原的表达分析及其在疾病分类和治疗策略中的应用
- 批准号:
25670726 - 财政年份:2013
- 资助金额:
$ 45.01万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research














{{item.name}}会员




